428
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis

ORCID Icon, , , & ORCID Icon
Pages 1730-1738 | Received 17 Dec 2019, Accepted 11 May 2020, Published online: 27 May 2020

References

  • Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. Jama. 2015;314(10):1039–1051.
  • Stroustrup A, Trasande L. Epidemiological characteristics and resource use in neonates with bronchopulmonary dysplasia: 1993–2006. Pediatrics. 2010;126(2):291–297.
  • Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2016;6:Cd001243.
  • Isayama T, Iwami H, McDonald S, et al. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. JAMA. 2016;316(6):611–624.
  • Isayama T, Chai-Adisaksopha C, McDonald SD. Noninvasive ventilation with vs without early surfactant to prevent chronic lung disease in preterm infants: a systematic review and meta-analysis. JAMA Pediatr. 2015;169(8):731–739.
  • Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern-Fetal Neo Med. 2014;27(16):1698–1702.
  • Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340(25):1962–1968.
  • Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008;1237:35–43.
  • Martin CR, Dasilva DA, Cluette-Brown JE, et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr. 2011;159(5):743–749.e1–e2.
  • Makrides M, Gibson RA, McPhee AJ, et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA: J Am Med Assoc. 2009;301(2):175–182.
  • Manley BJ, Makrides M, Collins CT, et al. High-dose docosahexaenoic acid supplementation of preterm infants: respiratory and allergy outcomes. Pediatrics. 2011;128(1):e71–e7.
  • Calder PC. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie. 2009;91(6):791–795.
  • Collins CT, Makrides M, McPhee AJ, et al. Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants. N Engl J Med. 2017;376(13):1245–1255.
  • Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration. 2011.
  • Higgins J, Lasserson T, Chandler J, et al. Methodological expectations of cochrane intervention reviews. Cochrane. 2016. Available at: https://community.cochrane.org/mecir-manual
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
  • Eisinga A. Embase animal filter; [cited 2020 May 17]. Available from: http://communitycochraneorg/sites/default/files/uploads/inline-files/Embase%20animal%20filterpdf. 2013.
  • Agarwal A, Johnston BC, Vernooij RW, et al. Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts. J Clin Epidemiol. 2017;81:3–12.
  • GRADEpro GDT. GRADEpro guideline development tool [software]. Canada: McMaster University; 2015. 435.
  • Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ (Clin Res ed). 2004;328(7454):1490.
  • Carlson SE, Werkman SH. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until two months. Lipids. 1996;31(1):85–90.
  • Werkman SH, Carlson SE. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until nine months. Lipids. 1996;31(1):91–97.
  • Smithers LG, Gibson RA, McPhee A, et al. Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status: results from the DINO trial. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):141–146.
  • Collins CT, Sullivan TR, McPhee AJ, et al. A dose response randomised controlled trial of docosahexaenoic acid (DHA) in preterm infants. Prostaglandins Leukot Essent Fatty Acids. 2015;99:1–6.
  • Richard C, Lewis ED, Field CJ. Evidence for the essentiality of arachidonic and docosahexaenoic acid in the postnatal maternal and infant diet for the development of the infant’s immune system early in life. Appl Physiol Nutr Metab. 2016;41(5):461–475.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.